Welcome to our dedicated page for Collplant Biotechnologies SEC filings (Ticker: CLGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding CollPlant’s breakthrough in plant-based rhCollagen often means combing through pages of scientific jargon, clinical trial tables, and royalty schedules. If you have ever searched for "CollPlant SEC filings explained simply" or wondered how a single 8-K can shift expectations for its AbbVie collaboration, you know the challenge. Our SEC Filings hub eliminates this friction, delivering every document the moment it hits EDGAR and translating technical language into plain English.
Need the numbers fast? Our AI reads each "CollPlant quarterly earnings report 10-Q filing" and delivers revenue by product class, burn-rate trends, and milestone payments in seconds. It flags "CollPlant 8-K material events explained" so you never miss a clinical update, and it tracks "CollPlant Form 4 insider transactions real-time" to reveal executive sentiment. Whether you’re comparing cash runway in the "CollPlant annual report 10-K simplified," dissecting dilution risk inside a proxy, or scanning "CollPlant executive stock transactions Form 4," our platform surfaces what matters and stores the full text for deeper review.
Beyond raw documents, Stock Titan layers expert context: AI-powered summaries spotlight how bioink revenue growth shows up in segment notes, while footnote extractions clarify royalty obligations tied to the Stratasys deal. Real-time alerts on "CollPlant insider trading Form 4 transactions" help monitor confidence ahead of FDA milestones, and side-by-side visuals support "CollPlant earnings report filing analysis" without spreadsheets. From "understanding CollPlant SEC documents with AI" to pinpointing "CollPlant proxy statement executive compensation," investors gain a clear view of the company’s progress in regenerative medicine—without wading through 300 pages of disclosures.
Moelis & Company (MC) filed a Form 4 reporting equity awards granted to non-employee director Kenneth Shropshire on 1 July 2025.
- 1,761 2025 Annual Restricted Stock Units (RSUs) were awarded at a reference price of $62.45 (average closing price for the five trading days ended 30 June 2025). The units vested immediately on the grant date, with share settlement scheduled within 60 days after 1 July 2027.
- 208 2025 Elective RSUs were awarded on the same date. These RSUs vest in four equal quarterly installments, concluding on 1 July 2026, and are settled within 60 days of each vesting date.
- Each RSU entitles the holder to receive one share of Class A common stock. Following the transactions, Shropshire beneficially owns the exact number of RSUs granted (1,761 and 208, respectively), reported as direct ownership.
The filing reflects routine director compensation rather than an open-market purchase or sale; therefore, immediate market impact is expected to be neutral.
FAQ
What is the current stock price of Collplant Biotechnologies (CLGN)?
What is the market cap of Collplant Biotechnologies (CLGN)?
What is CollPlant Biotechnologies Ltd. known for?
What is rhCollagen, and why is it significant?
What are CollPlant’s key products?
Who are CollPlant’s strategic partners?
What markets does CollPlant target?
What makes CollPlant’s products unique?
What is the significance of CollPlant’s regenerative breast implants?
How does CollPlant generate revenue?
What challenges does CollPlant face?
What are CollPlant’s sustainability initiatives?
